Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.16
+0.41001.03%
Pre-market: 40.300.1400+0.35%04:39 EDT
Volume:1.41M
Turnover:57.16M
Market Cap:2.87B
PE:-8.61
High:41.55
Open:40.38
Low:39.83
Close:39.75
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:0.82
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.74
PE(LYR):-8.61

Loading ...

FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy

Reuters
·
Jan 07

Vera Therapeutics Inc - Atacicept Receives FDA Breakthrough Therapy Designation for Igan

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults With Iga Nephropathy

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.

THOMSON REUTERS
·
Jan 07

Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects

Simply Wall St.
·
Dec 23, 2025

Vera Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 20, 2025

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 20, 2025

Vera Therapeutics Inc : Bofa Global Research Raises Price Objective to $66.00 From $48.00

THOMSON REUTERS
·
Dec 19, 2025

Vera Therapeutics Chief Legal Officer Jason Carter Departs

Reuters
·
Dec 18, 2025

Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares

Reuters
·
Dec 18, 2025

Director Patrick G. Enright Reports Acquisition of Vera Therapeutics Common Shares

Reuters
·
Dec 16, 2025

Vera Therapeutics (VERA): Valuation Check After $260 Million Stock Offering Ahead of Atacicept FDA Decision

Simply Wall St.
·
Dec 15, 2025

Vera Therapeutics Is Maintained at Neutral by Wedbush

Dow Jones
·
Dec 11, 2025

Vera Therapeutics Inc : Wedbush Raises Target Price to $33 From $23

THOMSON REUTERS
·
Dec 11, 2025

Wedbush Raises Price Target on Vera Therapeutics to $33 From $23, Keeps Neutral Rating

MT Newswires Live
·
Dec 11, 2025

Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Disposal of Common Shares

Reuters
·
Dec 11, 2025

Vera Therapeutics Prices $261 Million Public Offering

MT Newswires Live
·
Dec 10, 2025

BRIEF-Vera Therapeutics Prices Public Offering Of Class A Common Stock At $42.50 Per Share

Reuters
·
Dec 10, 2025

Vera Therapeutics Inc - Prices Public Offering at $42.50 per Share

THOMSON REUTERS
·
Dec 10, 2025